Skip to main content
Quest Diagnostics Home
Talk to an expert
Call
Menu

Primary care is the first line of defense for patients experiencing symptoms of autoimmune disorders

You know first-hand that recognizing autoimmune disease can be challenging due to vague, variable, and overlapping symptoms. That makes it even more important for you to get comprehensive autoimmune insights for your patients sooner, so you can make sure the next step on their healthcare journey is in the right direction. 

You are critical to helping improve patient outcomes

To support faster autoimmune diagnoses with fewer steps, we’ve developed a tool providing guidance on the clinical significance of results for ANA and 25 disease-specific biomarkers

Get the resource

It’s crucial to get earlier insights through comprehensive autoimmune screening

 Delayed autoimmune diagnosis and treatment can result in permanent joint and organ damage and lower the chance of remission.1 It’s more important than ever for PCPs to use comprehensive autoimmune screening solutions due to: 

Non-specificity with ANA screening 

Antinuclear antibody (ANA) screening alone is not disease-specific, meaning it requires more follow-up visits and testing.

Long wait time for rheumatologists 

6 weeks is the recommended time to visit a rheumatologist after symptom onset1 but current wait time for new patients is up to 6 months2

Recent increase of at-risk populations 

>100 million confirmed US COVID-19 cases,3 with data suggesting this population has a significantly higher risk of autoimmune disease4

 

 

Autoimmune symptoms may be complex, but getting answers doesn’t have to be

1 test code. 1 blood draw. 1 confident referral. More insights. Learn how our comprehensive screening panels deliver ANA results plus disease-specific insights you can translate into a more qualified referral and a faster path to diagnosis. 
Download the free guide
AI interpretation guide thumbnail

Help your patients get the care they need sooner

Reliable results

- Greater sensitivity with ANA gold-standard indirect fluorescent antibody (IFA) methodology

- Improved consistency through automation

Accessible testing

- Extensive network of ~2,000 Patient Service Centers

-Approximately 71% of patients do not receive a bill for ANAlyzeR5

- In-network with most health plans

Actionable insights

- Identifies multiple ANA patterns and disease-specific autoantibodies

- Expansive approach supports more informed referrals

Easy, simplified experience

- One blood draw reduces need for follow-up visits and tests

- Access to clinical consults and account support

ANAlyzeR - The analytic approach

ANAlyzeRTM ANA, IFA, with Reflex Titer/Pattern, Systemic Autoimmune Panel 1

Fixed panel of 25 analytes that gives a full-picture view (whether ANA is positive or negative), to support differential diagnosis, especially for patients with more than 1 autoimmune condition
View test details
Hereditary oncology spotlight

Cascade - The reflexive approach

ANA, IFA, Cascade and Rheumatoid Arthritis Panel 2, with Reflexes

Automatic reflex panel that tests for the 8 most common autoimmune diseases using a tiered cascade approach when ANA results are positive
View test details
Provider walking a patient through results

Your Quest expert is only a phone call away

Let’s discuss some of the key challenges your lab is facing and how we can work together to find the right solution for your diagnostic needs.

684

* indicates required

 

 

1. Niemantsverdriet E, Dougados M, Combe B, van der Helm-van Mil AHM. Referring early arthritis patients within 6 weeks versus 12 weeks after symptoms onset; an observational cohort study. Lancet Rheumatol. 2020;2(6):e332-e338. doi:10.1016/S2665- 9913(20)30061-8

2. American College of Rheumatology Responds to the Senate Health, Education, Pension, & Labor Committee. Published March 20, 2023. Accessed July 18, 2023. https://assets.contentstack.io/v3/ass ets/bltee37abb6b278ab2c/bl99244a 31c1fd18fe/acr-help-workforce-response.pdf

3. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization. Updated July 12, 2023. Accessed July 18, 2023. https://covid19.who.int/region/amro /country/us

4. Chang R, Yen-Ting Chen T, Wang SI, Hung YM, Chen HY, Wei CCJ. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. eClinicalMedicine. 2023;56:101783. doi:10.1016/j.eclinm.2022.101783

5. Data on file. Quest Diagnostics. March 2025.

Our company

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.